Back
 JCT  Vol.3 No.4 , August 2012
Novel Anti-Cancer Peptides Comprising Three Amino Acids
Abstract: Background: The NPxY motif common to all β integrin cytoplasmic domains forms part of a canonical recognition sequence for phosphotyrosine-binding domains which are protein modules present in a wide variety of signaling and cytoskeletal proteins. We have recently reported that a non-naturally occurring peptide, RSKAKNPLYR, derived from the β6 integrin cytoplasmic domain inhibits cancer cell growth in vitro and proposed that this may be due, at least in part, to the inhibition of c-Src activity [1]. In the present study we examined the role of the NPLY motif within RSKAKNPLYR in terms of its requirement for inhibition of cancer cell growth. Materials and Methods: The effects of peptide modifications to RSKAKNPLYR on in vitro proliferation of human cancer cell lines (colorectal HT29, prostate DU145, breast MCF-7 and ovarian A2780) were evaluated using the MTT cell growth assay. Passage of peptide across the plasma membrane was assessed by means of confocal microscopy using FITC-labelled peptide. The effect of peptide on kinase activity was assessed in cell-free in vitro kinase assays. Results: The NPLY motif within RSKAKNPLYR was found to be essential for the growth inhibitory effect of this peptide. However, modified forms of this peptide in which all amino acids except the charged residues arginine and lysine were replaced by single non-polar amino acids such as alanine or valine were equally effective at inhibiting cancer cell proliferation. Moreover, these peptides inhibited not only c-Src activity as seen for RSKAKNPLYR but also the activity of members of the PKB/Akt kinase family. Conclusion: Novel decapeptides comprising only three amino acids have anti-cancer effects without the requirement for an integrin-based NPLY motif. These peptides inhibit the activity of not only c-Src but also members of the Akt family of kinases and may be useful as potential anti-cancer agents when used either alone or in combination with compounds previously reported to inhibit c-Src kinase activity.
Cite this paper: M. Agrez, M. Garg and S. Ackland, "Novel Anti-Cancer Peptides Comprising Three Amino Acids," Journal of Cancer Therapy, Vol. 3 No. 4, 2012, pp. 230-236. doi: 10.4236/jct.2012.34033.
References

[1]   M. Agrez, M. Garg, D. Dorahy and S. Ackland, “Synergistic Anti-Tumor Effect of Cisplatin when Combined with an Anti-Src Kinase Integrin-Based Peptide,” Journal of Cancer Therapy, Vol. 2, No. 3, 2011, pp. 295-301. doi:10.4236/jct.2011.23039

[2]   R. O. Hynes, “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion,” Cell, Vol. 69, No. 1, 1992, pp. 11-25. doi:10.1016/0092-8674(92)90115-S

[3]   N. Ahmed, F. Pansino, R. Clyde, P. Murthi, M. A. Quinn, G. E. Rice, et al., “Overexpression of αvβ6 Integrin in Serous Epithelial Ovarian Cancer Regulates Extracellular Matrix Degradation via the Plasminiogen Activation Cascade,” Carcinogenesis, Vol. 23, No. 2, 2002, pp. 237-244. doi:10.1093/carcin/23.2.237

[4]   R. C. Bates, D. I. Bellovin, C. Brown, E. Maynard, B. Wu, H. Kawakatsu, et al., “Transcriptional Activation of Integrin β6 during the Epithelial-Mesenchymal Transition Defines a Novel Prognostic Indicator of Aggressive Colon Carcinoma,” Journal of Clinical Investigation, Vol. 115, No. 2, 2005, pp. 339-347.

[5]   N. Ahmed, J. Niu, D. J. Dorahy, X. H. Gu, S. Andrews, C. J. Meldrum, et al., “Direct Integrin αvβ6-ERK Binding: Implications for Tumour Growth,” Oncogene, Vol. 21, No. 9, 2002, pp. 1370-1380. doi:10.1038/sj.onc.1205286

[6]   Y. Takada, X. Ye and S. Simon, “Protein family Review— The Integrins,” Genome Biology, Vol. 8, No. 5, 2007, p. 215.

[7]   E. J. Filardo, P. C. Brooks, S. L. Deming, C. Damsky and D. A. Cheresh, “Requirement of the NPXY Motif in the Integrin Beta 3 Subunit Cytoplasmic Tail for Melanoma Cell Migration in Vitro and in Vivo,” Journal of Cell Biology, Vol. 130, 1995, pp. 441-450. doi:10.1083/jcb.130.2.441

[8]   M. V. Agrez, “Methods and Agents for the Treatment of Cancer,” International Patent Application, No. PCT/AU-2004/001416, Publication No. WO 2005/037308.

[9]   L. Bozulic, P. J. Morin, T. Hunter and B. A. Hemmings, “Meeting Report: Targeting the Kinome—20 Years Tyrosine Kinase Research in Basel,” Science STKE, Vol. 374, 2007, p. 8. doi:10.1126/stke.3742007pe8

[10]   J. Q. Cheng, C. W. Lindsley, G. Z. Cheng, H. Yang and S. V. Nicosia, “The AKT/PKB Pathway: Molecular Target for Cancer Drug Discovery,” Oncogene, Vol. 24, 2005, pp. 7482-7492. doi:10.1038/sj.onc.1209088

[11]   M. Sun, J. E. Paciga, R. I. Feldman, Z. Yuan, D. Coppola, Y. Y. Lu, et al., “Phosphotidylinositol-3-OH (PI3K)- AKT2, Activated in Breast Cancer, Regulates and Is Induced by Estrogen Receptor α (ERα) via Interaction between ERα and PI3K,” Cancer Research, Vol. 61, 2001, pp. 5985-5991.

[12]   J. Q. Cheng, B. Ruggeri, W. M. Klein, G. Sonoda, D. A. Altomare, D. K. Watson, et al., “Amplification of AKT2 in Human Pancreatic Cancer Cells and Inhibition of AKT2 Expression and Tumorigenicity by Antisense RNA,” Proceedings of the National Academy of Science USA, Vol. 93, No. 8, 1996, pp. 3636-3641. doi:10.1073/pnas.93.8.3636

[13]   K. E. Anderson, J. Coadwell, L. R. Stephens and P. T. Hawkins, “Translocation of PDK-1 to the Plasma Membrane Is Important in Allowing PDK-1 to Activate Protein Kinase B,” Current Biology, Vol. 8, No. 12, 1998, pp. 684-691. doi:10.1016/S0960-9822(98)70274-X

[14]   K. Nakatani, D. A. Thompson, A. Barthel, S. Hiroshi, W. Liu, R. J. Weigel, et al., “Upregulation of Akt3 in Estrogen Receptor-Deficient and Androgen Independent Prostate Cancer Cell Lines,” Journal of Biological Chemistry, Vol. 274, 1999, pp. 21528-21532. doi:10.1074/jbc.274.31.21528

[15]   T. A. Liby, P. Spyropoulos, H. B. Lindner, J. Eldridge, C. Beeson, T. Hsu, et al., “Akt3 Controls Vascular Endothelial Growth Factor Secretion and Angiogenesis in Ovarian Cancer Cells,” International Journal of Cancer, Vol. 130, No. 3, 2012, pp. 532-543 doi:10.1002/ijc.26010

[16]   T. G. Bivona, I. Perez De Castro, I. M. Ahearn, T. M. Grana, V. K. Chin, P. J. Lockyer, et al., “Phospholipase C gamma activates Ras on the Golgi apparatus by means of RasGRP1,” Nature, Vol. 424, No. 6949, 2003, pp. 694-698. doi:10.1038/nature01806

[17]   S. C. Dehm and K. Bonham, “SRC Gene Expression in Human Cancer: The Role of Transcriptional Activation,” Biochemistry and Cell Biology, Vol. 82, No. 2, 2004, pp. 263-274. doi:10.1139/o03-077

[18]   J. B. Bolen, A. Veillett, A. M. Schwartz, V. DeSeau and N. Rosen, “Activation of pp60c-src Protein Kinase Activity in Human Colon Carcinoma,” Proceedings of the National Academy of Science USA, Vol. 84, No. 8, 1987, pp. 2251-2255. doi:10.1073/pnas.84.8.2251

 
 
Top